Additionally, the commonly used drug for treating cough-variant asthma, montelukast sodium, was recently shown to reduce the inflammatory factor IL-4 and increase the anti-inflammatory factor interferon (IFN)-γ, thereby enhancing pulmonary function. This evidence concerns the gene IL4 and asthma.